1. Pink Sheet
  2. >>Vaccines

Expanded Distribution For COVID Vaccines Will Boost Options – And Logistical Complications

 
• By Derrick Gingery

Operation Warp Speed officials eye the Moderna vaccine and upcoming one-shot Janssen product to widen the immunization campaign’s reach, but more products also could bring more problems.

Slaoui_Moncef_1200 with mask 21Dec2020
Operation Warp Speed's Moncef Slaoui answers question during a 21 December briefing on COVID-19 vaccine development and distribution. • Source: Screenshot

New coronavirus vaccines are easing the logistical issues for Operation Warp Speed, while at the same time increasing their complexity, as the federal program attempts to vaccinate the entire United States in a matter of months.

Moderna, Inc.’s coronavirus vaccine, which received an emergency use authorization from the US Food and Drug Administration on 18 December, now is being distributed by OWS and its partners....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe

 
• By Francesca Bruce

The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.

Australia Looks To Modernize Human Tissue Laws, Improving Access For Researchers

 
• By Eliza Slawther

Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.

China NMPA Lays Out Regulatory Priorities At DIA

 
• By Xu Hu

At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.